Abstract
Introduction Electronic cigarette (e-cig) use in previously tobacco-naïve individuals may increase the risk of nicotine addiction and adverse health outcomes, including lung injury and cardiovascular disease. This study identifies a subgroup of heavy exclusive e-cig vapers, characterizes their demographics, and establishes an optimal serum cotinine threshold to differentiate them from tobacco-naïve individuals.
Methods We analyzed data from the National Health and Nutrition Examination Survey (2013– 2020) to characterize serum cotinine levels by e-cig use frequency. The optimal cotinine cutoff for identifying heavy exclusive vapers was 2.2 ng/mL (sensitivity 98%, specificity 96%).
We used receiver operating characteristic curve analysis to identify the cotinine threshold for discriminating heavy exclusive e-cig vapers from tobacco-naïve individuals and logistic regression to explore sociodemographic factors.
Results Exclusive heavy e-cig vapers—defined as those who vaped on four or more of the past five days—had mean cotinine levels (220 ± 38 ng/mL) comparable to cigarette smokers (212 ± 6 ng/mL). These vapers were more likely to be 12-18 (AOR 7.96; 95% CI: [3.38 – 18.7]) or 19-25 [AOR 7.36 [2.84 - 19]) years old and less likely to be female (AOR 0.3 [0.16-0.57]).
Conclusion Heavy exclusive e-cig vapers had serum cotinine levels similar to cigarette smokers and were predominantly young males. Public health interventions should target this high-risk subgroup to reduce potential long-term health consequences.
Competing Interest Statement
In the past three years, Harlan Krumholz received options for Element Science and Identifeye and payments from F-Prime for advisory roles. He is a co-founder of and holds equity in Hugo Health, Refactor Health, and Ensight-AI. He is associated with research contracts through Yale University from Johnson & Johnson, Kenvue, Novartis, and Pfizer. The other authors have no conflicts to disclose.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data is openly available through the NHANES website (https://wwwn.cdc.gov/nchs/nhanes/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos